year
old
male
histori
diabet
mellitu
type
recent
skin
infect
neck
underw
incis
drainag
levofloxacin
treatment
present
emerg
depart
day
histori
fever
cough
product
bloodi
sputum
short
breath
recent
return
trip
asia
tachycard
normotens
oxygen
satur
l
nasal
cannula
wbc
count
neutrophil
bun
creatinin
mgdl
mgdl
respect
glucos
mgdl
suspicion
cavitari
pneumonia
chest
radiograph
confirm
comput
tomographi
fig
would
best
empir
therapi
patient
answer
ceftriaxon
azithromycin
linezolid
patient
initi
admit
gener
medicin
unit
concern
meliodosi
base
travel
histori
patient
start
ceftazidim
azithromycin
vancomycin
develop
progress
hypoxemia
agit
requir
intub
mechan
ventil
bronchoscop
bronchoalveolar
lavag
bal
right
lower
lobe
reveal
wbc
neutrophil
sampl
rapidli
progress
pleural
effus
show
pleural
fluid
ph
glucos
mgdl
ldh
iul
gram
stain
fluid
reveal
cluster
gram
posit
cocci
chest
tube
drainag
right
pleural
space
perform
urinari
antigen
test
streptococcu
pneumonia
fungal
serolog
neg
empir
switch
vancomycin
linezolid
bal
pleural
fluid
cultur
subsequ
grew
methicillinresist
staphylococcu
aureu
mrsa
serum
immunoglobulin
ig
found
low
given
intraven
ig
prolong
icu
cours
ultim
transfer
acut
rehabilit
facil
subsequ
discharg
home
continu
receiv
intermitt
outpati
ivig
patient
admit
icu
sever
communityacquir
pneumonia
cap
gener
fall
one
two
categori
whose
symptom
sever
comorbid
condit
requir
icu
admiss
present
transfer
icu
later
progress
declin
despit
receiv
inpati
therapi
patient
need
mechan
ventil
vasopressor
support
septic
shock
automat
requir
intens
care
howev
decis
admit
icu
difficult
obviou
need
present
earli
identif
patient
like
deterior
import
increas
mortal
associ
icu
transfer
delay
respiratori
failur
onset
septic
shock
pool
analysi
four
prospect
cap
studi
delayedtransf
compar
direct
emerg
depart
ed
icu
admiss
demonstr
delayedtransf
group
higher
mortal
vs
p
hospit
length
stay
day
vs
day
p
propensitymatch
analysi
delay
transfer
icu
repres
progress
pneumonia
despit
appropri
treatment
mani
patient
subtl
clinic
find
upon
present
predict
aggress
approach
lead
improv
outcom
use
presenc
idsaat
minor
criteria
tabl
ed
beforeaft
qualiti
improv
project
demonstr
decreas
mortal
adjust
odd
ratio
confid
interv
ci
p
fewer
delay
icu
transfer
vs
p
minim
increas
direct
admiss
icu
aggress
preicu
assess
resuscit
protocol
util
commonli
use
pneumonia
sever
index
psi
score
use
predict
mortal
need
hospit
admiss
limit
abil
predict
need
intens
respiratori
monitor
vasopressor
support
initi
addit
idsaat
minor
criteria
sever
score
develop
gener
good
sensit
threshold
set
optim
howev
score
tool
lead
signific
increas
icu
admiss
follow
rigor
microorgan
respons
cap
icu
mirror
outpati
set
addit
gramneg
pathogen
mrsa
nine
studi
cap
patient
admit
icu
show
common
typic
bacteri
pathogen
pneumonia
l
pneumophila
haemophilu
influenza
enterobacteriacea
aureu
rel
frequenc
atyp
pathogen
icu
set
unclear
heterogen
diagnost
techniqu
test
frequenc
respiratori
virus
either
pure
coinfect
detect
sever
pneumonia
common
culprit
adult
includ
influenza
b
parainfluenza
viru
human
metapneumoviru
respiratori
syncyti
viru
adenoviru
much
less
common
viral
pathogen
includ
coronavirus
sar
viru
hantavirus
parechovirus
enterovirus
epidemiolog
risk
factor
potenti
help
suggest
less
common
etiolog
tabl
unfortun
sensit
risk
factor
low
empir
antibiot
treatment
usual
warrant
rather
enhanc
diagnost
test
exclud
etiolog
prudent
respons
aggress
diagnost
test
use
patient
sever
cap
requir
icu
admiss
patient
probabl
find
pathogen
resist
usual
cap
empir
therapi
eg
mrsa
increas
identif
specif
pathogen
lead
tailor
antimicrobi
thu
decreas
cost
exposur
unnecessari
medic
patient
invas
ventil
direct
access
lower
respiratori
tract
provid
opportun
perform
higher
yield
endotrach
aspir
bronchoalveolar
lavag
bal
cultur
prospect
studi
patient
admit
cap
bronchoscop
bal
provid
addit
diagnost
valu
patient
could
expector
sputum
treatment
failur
h
admiss
blood
sputum
cultur
low
sensit
still
perform
upon
transfer
icu
even
nonintub
patient
growth
inhibit
prior
antibiot
decreas
diagnost
yield
type
cultur
less
mrsa
gramneg
bacilli
etiolog
pleural
fluid
sampl
necessari
cap
patient
larg
pleural
effus
either
upon
admiss
one
develop
empir
treatment
cap
complic
pleural
space
requir
adequ
drainag
urinari
antigen
test
reason
sensit
excel
specif
detect
streptococcu
pneumonia
legionella
pneumophila
serogroup
test
remain
consider
includ
hypoglycemia
nondiabet
patient
acut
alcoholismwithdraw
hyponatremia
unexplain
metabol
acidosi
elev
lactat
level
cirrhosi
asplenia
b
need
noninvas
ventil
substitut
respiratori
rate
breathsmin
pao
fio
c
result
infect
alon
posit
day
patient
pneumonia
week
l
pneumophila
although
antibiot
sensit
data
obtain
isol
pathogen
resist
usual
therapi
actual
uncommon
therapi
appropri
modifi
specif
cover
either
pathogen
viral
test
import
virus
increas
recogn
import
caus
scap
particularli
immunocompromis
patient
standard
viral
diagnosi
polymeras
chain
reaction
pcr
often
multiplex
panel
posit
influenza
test
criticallyil
patient
impetu
antivir
therapi
hasten
diseas
resolut
decreas
spread
benefit
posit
assay
virus
influenza
remain
unclear
treatment
option
antibiot
rare
held
viral
detect
given
low
sensit
test
bacteri
etiolog
despit
aggress
cultur
routin
diagnost
test
major
case
cap
includ
scap
remain
without
definit
etiolog
even
research
techniqu
routin
use
increas
number
usual
pathogen
detect
rather
resist
rare
pathogen
pcr
test
usual
bacteria
emerg
option
intub
patient
cap
pcr
becom
standard
mycoplasma
chlamydophila
recent
studi
demonstr
mrsa
pcr
highli
sensit
avoid
antimrsa
treatment
safe
bal
sampl
pcr
neg
multiplex
bacteri
pcr
panel
approv
fda
clinic
studi
treatment
base
result
test
still
need
sever
cap
time
diagnosi
adequ
empir
antimicrobi
therapi
paramount
similar
data
septic
shock
appropri
antibiot
treatment
within
h
admiss
associ
significantli
lower
mortal
sever
cap
adequ
coverag
pneumonia
methicillinsuscept
aureu
mssa
l
pneumophila
crucial
adequ
absenc
risk
factor
drugresist
pathogen
combin
antibiot
betalactam
ceftriaxon
cefotaxim
ampicillinsulbactam
either
macrolid
fluoroquinolon
strongli
recommend
prospect
random
control
trial
rct
nonicu
inpati
demonstr
improv
clinic
outcom
betalactam
combin
therapi
compar
monotherapi
ident
betalactam
confirm
multipl
observ
retrospect
studi
show
better
clinic
outcom
mortal
combin
therapi
especi
bacterem
pneumococc
pneumonia
mrsa
pneumonia
linezolid
superior
vancomycin
particularli
toxinsecret
communityacquir
strain
culprit
doubleblind
rct
compar
linezolid
doseadjust
vancomycin
treatment
proven
mrsa
nosocomi
pneumonia
demonstr
camrsa
communityacquir
methicillinresist
staphylococcu
aureu
copd
chronic
obstruct
pulmonari
diseas
sar
sever
acut
respiratori
syndrom
erad
mrsa
clinic
cure
statist
better
linezolid
less
nephrotox
mssa
betalactam
therapi
still
treatment
choic
caprel
pleural
effus
chemistri
cultur
thoracentesi
fluid
distinguish
uncompl
parapneumon
effus
upp
complic
parapneumon
effus
cppe
empyema
optim
threshold
still
matter
debat
ph
glucos
mgdl
andor
ldh
level
iul
suggest
cppe
empyema
necess
pleural
drainag
achiev
good
outcom
contrast
upp
usual
exud
pleural
fluid
ph
normal
glucos
upp
reactiv
resolv
appropri
antibiot
therapi
optim
therapi
cppe
empyema
hing
combin
adequ
antibiot
coverag
pleural
drainag
locul
develop
rct
intrapleur
dnase
concomit
tissu
plasminogen
activ
patient
empyema
show
lower
rate
surgic
referr
hospit
length
stay
placebo
agent
alon
lysi
adhes
decort
via
videoassist
thoracoscop
surgeri
thoracotomi
may
necessari
less
invas
measur
fail
sever
aspect
sever
cap
manag
remain
controversi
includ
assess
risk
multidrug
resist
mdr
pathogen
assess
tool
adjunct
treatment
broad
spectrum
empir
antibiot
therapi
sever
cap
hing
risk
drug
resist
organ
pseudomona
mrsa
sever
icu
studi
suggest
risk
patient
previous
healthcareassoci
pneumonia
hcap
categori
use
identifi
patient
develop
pneumonia
outsid
hospit
yet
risk
resist
pathogen
usual
associ
nosocomi
pneumonia
hcap
criteria
origin
develop
pneumonia
use
result
signific
overtreat
broad
spectrum
antibiot
associ
increas
mortal
convers
ignor
risk
factor
associ
undertreat
advers
outcom
prospect
observ
studi
shindo
et
al
found
six
independ
risk
factor
pathogen
resist
usual
cap
antibiot
hospit
day
previou
day
antibiot
use
previou
day
nonambulatori
statu
tube
feed
immunocompromis
statu
use
gastric
acid
suppress
medic
mrsa
risk
factor
slightli
differ
overlap
importantli
two
risk
factor
requir
frequenc
mdr
pathogen
justifi
empir
broadspectrum
therapi
result
far
less
use
still
identifi
major
would
need
broadspectrum
therapi
new
cap
guidelin
offer
altern
hcap
criteria
also
need
valid
almost
scap
patient
document
pneumonia
die
despit
antibiot
resist
clearli
antibiot
resist
andor
unusu
pathogen
major
caus
persist
high
scap
mortal
one
explan
toxin
product
common
pathogen
particular
staphylococcu
streptococcu
sp
gram
posit
bacteria
often
produc
exotoxin
compon
pathogenesi
aureu
pantonvalentin
leukocidin
pvl
exotoxin
classic
exampl
presenc
pvl
may
explain
associ
neutropenia
exotoxin
may
result
characterist
sever
pulmonari
hemorrhag
mrsa
mssa
infect
communityacquir
mrsa
camrsa
clone
distinct
usual
caus
nosocomi
pneumonia
emerg
caus
pneumonia
strike
necrot
featur
antibiot
therapi
also
suppress
toxin
product
provid
better
outcom
improv
surviv
illustr
retrospect
studi
pvlposit
cap
clindamycin
linezolid
suppress
vitro
format
pvl
toxic
shock
syndrom
wherea
vancomycin
betalactam
effect
benefit
clindamycin
mssa
isol
resist
suscept
test
unclear
sinc
correl
suscept
toxinsuppress
activ
uncertain
prefer
treatment
pvlposit
mssa
cap
still
unclear
linezolid
appear
reason
choic
camrsa
cap
light
potenti
suppress
exotoxin
greater
erad
mrsa
clone
pneumonia
exotoxin
product
may
partial
explain
longstand
controversi
need
macrolid
combin
therapi
especi
bacterem
sever
cap
case
host
immunomodul
concomit
atyp
bacteri
coinfect
postul
major
mechan
howev
macrolid
also
suppress
product
pneumolysin
potent
exotoxin
involv
mani
manifest
sever
pneumococc
diseas
phenomenon
may
also
explain
macrolid
combin
fluoroquinolon
also
synergist
despit
overlap
antibacteri
spectrum
procalcitonin
pct
peptid
releas
respons
bacteri
infect
suppress
interferon
induc
viral
infect
potenti
distinguish
bacteri
viral
caus
pneumonia
potenti
guid
antibiot
decis
howev
major
viral
pneumonia
sever
enough
requir
icu
admiss
elev
pct
level
whether
reflect
occult
bacteri
superinfect
proinflammatori
respons
sever
viral
pneumonia
overcom
interferon
suppress
unclear
persist
elev
pct
level
associ
advers
outcom
develop
pneumonia
complic
death
sinc
failur
erad
bacteri
caus
unusu
death
cap
may
result
inappropri
perhap
exagger
host
respons
infect
investig
therefor
attempt
modul
inflammatori
respons
scap
corticosteroid
sever
small
retrospect
studi
support
corticosteroid
administr
scap
larger
doubleblind
rct
patient
scap
defin
psi
iv
v
fail
show
benefici
effect
corticosteroid
convers
highli
select
group
scap
patient
high
creactiv
protein
level
admiss
use
corticosteroid
associ
less
treatment
failur
caution
corticosteroid
use
warrant
known
influenza
pneumonia
sinc
wors
outcom
report
case
inappropri
host
respons
also
immunosuppress
sometim
occult
illustr
case
scap
warrant
consider
alter
host
immun
especi
famili
histori
death
infect
use
ecmo
emerg
issu
scap
manag
ecmo
use
underw
resurg
influenza
pandem
recent
studi
ecmo
includ
disproportion
number
pneumonia
compar
caus
ard
preponder
pneumonia
ecmo
seri
may
alveoli
fill
pneumon
infiltr
less
amen
improv
higher
level
peep
recruit
maneuv
includ
prone
posit
